New Delhi: The Indian multinational biotechnology company Bharat Biotech on June 3 said “Our Covaxin vaccine is overall 77.8 percent effective against Covid. Bharat Biotech’s final analysis from Phase 3 trial data shows that Covaxin is 65 percent effective against Delta variant.”
Bharat Biotech claims they conducted the largest efficacy trial in India with 25,800 participants across 25 trial sites.
The Company in its official statement said that “Phase III data has found Covaxin to be 78 percent effective against mild, moderate and severe COVID-19 and Age group of the vaccine trial participants ranged from 18-98 years. It was found to be 93 percent effective against severe COVID-19 – reducing hospitalizations.”
The company further added that “Covaxin has been ‘well-tolerated among participants and showed “minimal adverse effects post-immunization. The study has not yet peer-reviewed. It has been published on medrxiv.”
Meanwhile, the Hyderabad-based firm has applied to the World Health Organization (WHO) for the emergency-use listing of its coronavirus vaccine candidate Covaxin, which is among the three COVID-19 vaccines currently being administered in India.
Covaxin has received emergency use authorizations in 16 countries including, Brazil, India, the Philippines, Iran, Mexico. The company is in discussions with WHO to obtain an emergency use listing for Covaxin. The product has been exported to several countries with additional requests for supplies being received.
Located in Genome Valley in Hyderabad, Bharat Biotech has delivered more than 4 billion doses of vaccines worldwide. The company has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune.
Suchitra Ella, Bharat Biotech co-founder late-night tweeted that “We are proud to put India on the global map with scientific conviction, competence, and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy.”
Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “The successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever Covid vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product development. We are proud to state that Innovation from India will now be available to protect the global population.”
“The successful development of Covaxin has consolidated the position of Indian academia and industry in the global arena,” Prof. (Dr) Balram Bhargava, Secretary Department of Health Research & Director General Indian Council of Medical Research, said.
